Linus Görlitz, Michael Block, Jörg Lippert Identifying cancer drug MoAs and cell-line properties using signaling cascade models and Bayesian analysis: From throw-away experiments to persistent information
|
Michael Block, Linus Görlitz, Clara Happ, Rolf Burghaus, Jörg Lippert Separating individual physiological variability from drug related properties using PBPK Modeling with PK-Sim® and MoBi® – Theophylline
|
Thomas Eissing, Michael Block, Katrin Coboeken, Thomas Gaub, Lars Kuepfer, Michaela Meyer, Michael Sevestre, Juri Solodenko, Joerg Lippert Clinical trial simulation with multiscale models: Integrating whole-body physiology, disease biology, and molecular reaction networks
|
Christoph Niederalt(1), Lars Kuepfer(1), Thomas Wendl(1), Stefan Willmann(1), Jörg Lippert(1), Victoria Flores(2) & Piet van der Graaf(2) Mechanistic analysis of fusion proteins: PBPK applied in an Albuferon case study
|
M. Meyer, L. Kuepfer, D. Chandra Prakash, S. Schneckener, B. Ludewig, J. Lippert Using relative gene expression measurements for PBPK modeling of pravastatin
|
M. Meyer (1), S. Willmann (1), C. Becker (2), R. Burghaus (2), W. Mueck (2), J. Lippert (1) Influence of CYP1A1 induction by cigarette smoke on pharmacokinetics of erlotinib: a computer-based evaluation of smoke-induced CYP1A1 activity in different tissues
|
J. Lippert(1), K. Boland(2), S. Willmann(1), E. Hizaler Hoffmann(1), A. Sensse(1), M. Sevestre(1), R. Pyke(3), A. Staab(2) Simulation of the pharmacokinetics of flibanserin under itraconazole co-mediaction with an integrated physiologically-based pharmacokinetic model
|